The analysis and distribution of pharmaceuticals in tissue is increasingly important in understanding the full action of drugs in vivo. Across molecular types from very small molecules to larger peptides and oligonucleotides, bioanalysis of tissues presents unique challenges inherent quantitative bioanalysis in a mixed matrix assay.
This poster:
- Describes a method of processing to mitigate binding and suppression effects in tissue homogenates
- Demonstrate surrogate curves are effective at compensating for matrix effects in multiple matrices
- Demonstrate increased workflow efficiency and acceptable assay performance using a single surrogate curve for multiple tissues.
Download Document
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Automation within an ADME Laboratory
Taking an assay from bench to an automated platform
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Strategies for Effective Neutralizing Cell Based Assays in Early Immunogenicity Risk Assessment
Quantitative Assays for Peptides using LC-MS
Quantitative high-throughput analysis of peptide therapeutics and biomarkers to regulated bioanalytical standards
Hybrid Assays for Protein Bioanalysis
Combining immuno-affinity with liquid chromatography-mass spectrometry (LC-MS)
Absolute Bioavailability Analysis Using Stable Isotopes
A Liquid Chromatography-Tandem Mass Spectrometry Approach
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
